SCHEMBL6759838

SCHEMBL6759838

CCOC(=O)c1cc(OC(=O)c2ccccc2)c(OC(=O)c2ccccc2)c(OC(=O)c2ccccc2)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.50
ALDH1A1 P00352 5/20 0.50
LMNA P02545 2/20 0.50
TSHR P16473 1/20 0.49
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
SLC6A3 Q01959 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
HSD17B10 Q99714 1/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
NOD2 Q9HC29 1/20 0.43
HSP90AA1 P07900 1/20 0.43
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
MAOB P27338 1/20 0.42
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6760438 0.91 LMNA (0.56) KMT2AALDH1A1LMNATSHRSLC6A3
SCHEMBL6761423 0.89 TSHR (0.52) KMT2AALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL6759803 0.88 TDP1 (0.54) KMT2AALDH1A1LMNATSHRSLC6A3
SCHEMBL6759718 0.88 TSHR (0.53) KMT2AALDH1A1LMNATSHRNPC1
SCHEMBL6761470 0.87 ALDH1A1 (0.54) KMT2AALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL6763875 0.87 ALDH1A1 (0.54) KMT2AALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL6763231 0.86 SLC6A3 (0.61) KMT2AALDH1A1TSHRGAASMN1; SMN2
SCHEMBL6766605 0.86 ESR1 (0.54) KMT2ALMNATSHRGAASMN1; SMN2
SCHEMBL6767307 0.86 KMT2A (0.47) KMT2AALDH1A1LMNATSHRGAA
SCHEMBL6764009 0.83 KMT2A (0.54) KMT2AALDH1A1LMNAGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040247698-A1 Erectile Dysfunction Treatment VALENZUELA CORTES CARMEN MARIA (CL) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040247698-A1 Erectile Dysfunction Treatment PDE3A, PDE3B, PDE12 KMT2A 2816/4885ALDH1A1 1744/4885LMNA 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.